title: Impact of Breast Cancer Subtype Defined by Immunohistochemistry Hormone Receptor and HER2 Status on the Incidence of Immediate Postmastectomy Reconstruction.
abstract: Immediate postmastectomy reconstruction has become an increasingly popular choice for breast cancer patients recently. However, whether molecular subtype of cancer impacts the incidence of breast reconstruction is unclear. We aimed to investigate the association between breast cancer subtype defined by immunohistochemistry hormone receptor (HR) and human epidermal growth factor receptor 2 (HER2) status and recent rates of immediate postmastectomy reconstruction in the United States.The National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) database was used to evaluate stage I-III breast cancer patients with different subtypes who underwent either mastectomy alone or mastectomy plus reconstruction between 2010 and 2012. Univariate and multivariate analyses were conducted to identify factors influencing the incidence of immediate reconstruction.Of 47,123 women included, 33.1% (10,712/32,376) of HR+/HER2-, 33.1% (1912/5768) of HR+/HER2+, 29.6% (850/2875) of HR-/HER2+, and 27.7% (1689/6104) of triple negative breast cancer patients received immediate breast reconstruction (chi-square test, P < 0.001), respectively. Thus, HER2-overexpressing and triple negative breast cancer patients received significantly less breast reconstruction. After adjusting for demographic, socioeconomic, geographic, or clinicopathologic factors, HER2-overexpressing (OR 0.896, 95% CI 0.817-0.984) and triple negative (OR 0.806, 95% CI 0.751-0.866) breast cancer patients remained less likely to undergo immediate postmastectomy reconstruction compared with HR+/HER2- or HR+/HER2+ patients. No significant difference was found in the type of reconstruction among different subtypes. Subgroup analysis showed that the difference of breast reconstruction rates among distinct subtypes varied with different grade and stage groups, and the association between breast cancer subtype and the reconstruction rate was not significant in low grade and early stage patients.This population-based study determined that breast cancer subtype was an independent predictor for the utilization of immediate postmastectomy reconstruction. Patients with HER2-overexpressing or triple negative breast cancer subtype that has relatively higher risk of local recurrence, were less likely to receive immediate breast reconstruction than those with luminal tumors. Further studies are needed to disclose more underlying reasons of different reconstruction incidences for distinct subtypes of breast cancer.
authors.affiliation: From the Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Department of Breast Surgery, Breast Tumor Center (WW, HD, JW); Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Department of Anesthesiology (SC, MC); and Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Department of General Surgery, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China (KM).
authors.forename: Wei
authors.initials: W
authors.lastname: Wu
authors.forename: Shi
authors.initials: S
authors.lastname: Cheng
authors.forename: Heran
authors.initials: H
authors.lastname: Deng
authors.forename: Jiannan
authors.initials: J
authors.lastname: Wu
authors.forename: Kai
authors.initials: K
authors.lastname: Mao
authors.forename: Minghui
authors.initials: M
authors.lastname: Cao
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D001940:Breast / Q000473:pathology / Q000601:surgery*; D001943:Breast Neoplasms / Q000473:pathology / Q000601:surgery*; D005260:Female; D006801:Humans; D008408:Mastectomy / Q000706:statistics & numerical data*; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism*; D011960:Receptors, Estrogen / Q000378:metabolism; D011980:Receptors, Progesterone / Q000378:metabolism; D019651:Plastic Surgery Procedures / Q000706:statistics & numerical data*; D012307:Risk Factors; D013997:Time Factors; D014481:United States; D055815:Young Adult
chemical_list: D018719:Erb-b2 Receptor Tyrosine Kinases; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; C508053:ERBB2 protein, human
references.citation: Breast Cancer Res Treat. 2011 Jun;127(2):439-46
references.pmid: 21409394
references.citation: Med Care. 2010 Oct;48(10):892-9
references.pmid: 20808256
references.citation: Lancet. 1983 Feb 26;1(8322):459-62
references.pmid: 6131178
references.citation: Ann Oncol. 2008 Aug;19(8):1430-1434
references.pmid: 18390839
references.citation: Eur J Surg Oncol. 2013 Mar;39(3):260-5
references.pmid: 23313014
references.citation: J Clin Oncol. 2010 Jul 10;28(20):3271-7
references.pmid: 20498394
references.citation: J Surg Res. 2015 May 1;195(1):368-76
references.pmid: 25676466
references.citation: Breast Cancer Res. 2005;7(2):R184-93
references.pmid: 15743498
references.citation: Breast Cancer Res Treat. 2008 Dec;112(3):545-9
references.pmid: 18210199
references.citation: Cancer. 2009 Oct 15;115(20):4648-54
references.pmid: 19634163
references.citation: J Am Coll Surg. 2012 Mar;214(3):270-6
references.pmid: 22225646
references.citation: Clin Cancer Res. 2007 Apr 15;13(8):2329-34
references.pmid: 17438091
references.citation: Ann Surg. 2006 Feb;243(2):241-9
references.pmid: 16432358
references.citation: J Natl Cancer Inst. 2000 Sep 6;92(17):1422-9
references.pmid: 10974078
references.citation: Arch Pathol Lab Med. 2010 Jul;134(7):e48-72
references.pmid: 20586616
references.citation: Ann Plast Surg. 2008 Jul;61(1):11-8
references.pmid: 18580143
references.citation: Breast J. 2011 Jul-Aug;17(4):352-8
references.pmid: 21615823
references.citation: Plast Reconstr Surg. 2008 Feb;121(2):381-388
references.pmid: 18300953
references.citation: Am J Surg. 2009 Aug;198(2):237-43
references.pmid: 19306977
references.citation: Plast Reconstr Surg. 2003 Feb;111(2):695-703; discussion 704-5
references.pmid: 12560690
references.citation: JAMA Surg. 2014 Oct;149(10):1015-21
references.pmid: 25141939
references.citation: Ann Surg Oncol. 2013 Jun;20(6):1872-9
references.pmid: 23263733
references.citation: Breast Cancer Res Treat. 2012 Jun;133(3):831-41
references.pmid: 22147079
references.citation: Clin Cancer Res. 2005 Aug 15;11(16):5678-85
references.pmid: 16115903
references.citation: Plast Reconstr Surg. 2015 Feb;135(2):270e-276e
references.pmid: 25626810
references.citation: J Natl Cancer Inst. 2014 Apr 28;106(5):
references.pmid: 24777111
references.citation: Breast. 2011 Oct;20(5):437-43
references.pmid: 21601458
references.citation: Mol Oncol. 2011 Feb;5(1):5-23
references.pmid: 21147047
references.citation: JAMA. 2006 Jun 7;295(21):2492-502
references.pmid: 16757721
references.citation: Cancer. 2008 Mar 1;112(5):1178-87
references.pmid: 18253948